NT-proBNP in systemic right ventricles: a new cutoff level for risk stratification?
Gespeichert in:
| Titel: | NT-proBNP in systemic right ventricles: a new cutoff level for risk stratification? |
|---|---|
| Autoren: | Tran, Fabian, Ruperti-Repilado, Francisco Javier, Haaf, Philip, Lopez-Ayala, Pedro, Greutmann, Matthias, Schwerzmann, Markus, Bouchardy, Judith, Gabriel, Harald, Stambach, Dominik, Schwitter, Juerg, Wustmann, Kerstin, Freese, Michael, Mueller, Christian, Tobler, Daniel |
| Weitere Verfasser: | University of Zurich, Tobler, Daniel |
| Quelle: | Revista espanola de cardiologia, vol. 78, no. 2, pp. 107-116 Tran, Fabian; Ruperti-Repilado, Francisco Javier; Haaf, Philip; Ayala, Pedro Lopez; Greutmann, Matthias; Schwerzmann, Markus; Bouchardy, Judith; Gabriel, Harald; Stambach, Dominik; Schwitter, Juerg; Wustmann, Kerstin; Freese, Michael; Mueller, Christian; Tobler, Daniel (2024). NT-proBNP in systemic right ventricles: a new cutoff level for risk stratification? (In Press). Revista española de cardiología-English Edition Elsevier Doyma 10.1016/j.rec.2024.05.006 <http://dx.doi.org/10.1016/j.rec.2024.05.006> Tran, Fabian; Ruperti-Repilado, Francisco Javier; Haaf, Philip; Ayala, Pedro Lopez; Greutmann, Matthias; Schwerzmann, Markus; Bouchardy, Judith; Gabriel, Harald; Stambach, Dominik; Schwitter, Juerg; Wustmann, Kerstin; Freese, Michael; Mueller, Christian; Tobler, Daniel (2025). NT-proBNP in systemic right ventricles: a new cutoff level for risk stratification? Revista española de cardiología-English Edition, 78(2), pp. 107-116. Elsevier Doyma 10.1016/j.rec.2024.05.006 <http://dx.doi.org/10.1016/j.rec.2024.05.006> |
| Verlagsinformationen: | Elsevier BV, 2025. |
| Publikationsjahr: | 2025 |
| Schlagwörter: | 03 medical and health sciences, 0302 clinical medicine, Humans, Natriuretic Peptide, Brain/blood, Peptide Fragments/blood, Female, Male, Middle Aged, Prognosis, Adult, Risk Assessment/methods, Heart Ventricles/physiopathology, Heart Ventricles/diagnostic imaging, Biomarkers/blood, Ventricular Function, Right/physiology, Stroke Volume/physiology, Ventricular Dysfunction, Right/blood, Ventricular Dysfunction, Right/physiopathology, Follow-Up Studies, Echocardiography, Survival Rate/trends, Biomarcadores, Biomarkers, Cardiopatías congénitas del adulto, Congenital heart disease, Heart Failure, Insuficiencia cardiaca, Transposición de las grandes arterias, Transposition of the great arteries, 10209 Clinic for Cardiology, 610 Medicine & health, 2705 Cardiology and Cardiovascular Medicine, 3. Good health |
| Beschreibung: | The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the risk prediction of patients with systemic right ventricles (sRV) is not well defined. The aim of this study was to analyze the prognostic value of NT-proBNP in patients with an sRV.The prognostic value of NT-proBNP was assessed in 98 patients from the SERVE trial. We used an adjusted Cox proportional hazards model, survival analysis, and c-statistics. The composite primary outcome was the occurrence of clinically relevant arrhythmia, heart failure, or death. Correlations between baseline NT-proBNP values and biventricular volumes and function were assessed by adjusted linear regression models.The median age [interquartile range] at baseline was 39 [32-48] years and 32% were women. The median NT-proBNP was 238 [137-429] ng/L. Baseline NT-proBNP concentrations were significantly higher among the 20 (20%) patients developing the combined primary outcome compared with those who did not (816 [194-1094] vs 205 [122-357]; P=.003). In patients with NT-proBNP concentrations> 75th percentile (> 429 ng/L), we found an exponential increase in the sex- and age-adjusted hazard ratio for the primary outcome. The prognostic value of NT-proBNP was comparable to right ventricular ejection fraction and peak oxygen uptake on exercise testing (c-statistic: 0.71, 0.72, and 0.71, respectively).In patients with sRVs, NT-proBNP concentrations correlate with sRV volumes and function and may serve as a simple tool for predicting adverse outcomes. |
| Publikationsart: | Article Other literature type |
| Dateibeschreibung: | application/pdf; ZORA_270755.pdf - application/pdf |
| Sprache: | English |
| ISSN: | 1885-5857 |
| DOI: | 10.1016/j.rec.2024.05.006 |
| DOI: | 10.5167/uzh-270755 |
| DOI: | 10.48350/197654 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/38844073 https://serval.unil.ch/notice/serval:BIB_4949D3E0FADB https://serval.unil.ch/resource/serval:BIB_4949D3E0FADB.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_4949D3E0FADB3 https://boris.unibe.ch/197654/ |
| Rights: | CC BY |
| Dokumentencode: | edsair.doi.dedup.....c8dcb38953bca16167625e9bc30c19ec |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the risk prediction of patients with systemic right ventricles (sRV) is not well defined. The aim of this study was to analyze the prognostic value of NT-proBNP in patients with an sRV.The prognostic value of NT-proBNP was assessed in 98 patients from the SERVE trial. We used an adjusted Cox proportional hazards model, survival analysis, and c-statistics. The composite primary outcome was the occurrence of clinically relevant arrhythmia, heart failure, or death. Correlations between baseline NT-proBNP values and biventricular volumes and function were assessed by adjusted linear regression models.The median age [interquartile range] at baseline was 39 [32-48] years and 32% were women. The median NT-proBNP was 238 [137-429] ng/L. Baseline NT-proBNP concentrations were significantly higher among the 20 (20%) patients developing the combined primary outcome compared with those who did not (816 [194-1094] vs 205 [122-357]; P=.003). In patients with NT-proBNP concentrations> 75th percentile (> 429 ng/L), we found an exponential increase in the sex- and age-adjusted hazard ratio for the primary outcome. The prognostic value of NT-proBNP was comparable to right ventricular ejection fraction and peak oxygen uptake on exercise testing (c-statistic: 0.71, 0.72, and 0.71, respectively).In patients with sRVs, NT-proBNP concentrations correlate with sRV volumes and function and may serve as a simple tool for predicting adverse outcomes. |
|---|---|
| ISSN: | 18855857 |
| DOI: | 10.1016/j.rec.2024.05.006 |